|1.||Grever, Michael R: 13 articles (01/2015 - 03/2003)|
|2.||Byrd, John C: 8 articles (01/2015 - 04/2005)|
|3.||Kay, Neil E: 7 articles (09/2015 - 01/2004)|
|4.||Ravandi, Farhad: 6 articles (12/2015 - 01/2006)|
|5.||Vogelsang, Georgia B: 6 articles (11/2009 - 07/2003)|
|6.||Call, Timothy G: 5 articles (09/2015 - 01/2007)|
|7.||Shanafelt, Tait D: 5 articles (09/2015 - 01/2007)|
|8.||Zent, Clive S: 5 articles (07/2014 - 01/2007)|
|9.||Catovsky, Daniel: 5 articles (06/2011 - 10/2003)|
|10.||Matutes, Estella: 5 articles (06/2011 - 10/2003)|
|1.||Hairy Cell Leukemia
01/01/2003 - "Pentostatin is a highly effective regimen for hairy cell leukemia that produces durable complete responses. "
07/01/2001 - "Although most patients with hairy cell leukemia in Japan have the Japanese variant, and the European-American type is rare, pentostatin is as effective as it is for European and American patients."
11/01/2000 - "Pentostatin is a highly effective regimen for hairy cell leukemia that produces durable complete responses. "
04/01/2000 - "Pentostatin is a highly effective agent for hairy cell leukemia and produces prolonged remissions in the majority of patients."
11/01/1986 - "Low-dose deoxycoformycin administered intravenously every other week represents an extremely effective treatment for hairy cell leukemia."
04/01/2006 - "Early clinical trials with pentostatin used high doses for acute lymphoblastic leukemias, which were characterized by high levels of ADA. "
01/01/1987 - "Biochemical mechanisms of deoxycoformycin toxicity in chronic leukemias."
01/01/1984 - "Biochemical basis for the differential effects of deoxycoformycin on human leukemias."
01/01/1984 - "We examined the in vivo effects of a potent inhibitor of ADA, 2'-deoxycoformycin, which was used to treat a patient with refractory acute leukemia. "
10/01/1983 - "Increased cytotoxicity of N6-(delta 2-isopentenyl)adenosine in combination with pentostatin against L-1210 leukemia cells."
06/01/1988 - "Promising results in the treatment of indolent lymphomas have been reported with the use of 2'deoxycoformycin. "
03/01/1996 - "Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group."
04/01/1991 - "Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease."
09/01/2003 - "Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes."
07/15/1991 - "Transport of 2'-deoxycoformycin in human leukemic and lymphoma cells."
08/01/2002 - "The pentostatin doses used in the study appear to be appropriate for administration to cancer patients with varying degrees of renal impairment."
03/01/2005 - "Present and previous data reviewed here demonstrates the striking cytotoxic activity of Pentostatin against gammadelta+ tumor T cells. "
01/01/1996 - "It was anticipated that pentostatin would be most active in neoplasms with high intracellular concentrations of ADA, e.g. "
01/01/1996 - "It was hypothesized that pentostatin would be lymphocytotoxic and this proved to be true; this finding prompted its investigation in lymphoid neoplasms. "
09/01/1990 - "Pentostatin (2'-deoxycoformycin) for the treatment of lymphoid neoplasms."
11/01/1992 - "After administration of deoxycoformycin (DCF) at a dose of 5.0mg/m2 1-2 times monthly, splenomegaly disappeared, as did hairy cells from the peripheral blood. "
05/01/2001 - "[European-American-type hairy cell leukemia without splenomegaly, treated successfully with deoxycoformycin]."
12/01/1984 - "A woman with hairy-cell leukemia has begun treatment with pentostatin, and at ten weeks there is disappearance of gross splenomegaly and clearance of hairy cells from the blood. "
04/01/1995 - "A multivariate logistic regression analysis of the confirmed complete remissions on pentostatin showed the following factors to be important for achieving a complete remission: high hemoglobin level (two-tailed P = .024), young age (P = .0085), and no or little splenomegaly (P = .0029). "
|4.||Interferon-alpha (Interferon Alfa)
|4.||Drug Therapy (Chemotherapy)
|5.||Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)